26 completed, 11 recruiting, 5 active not recruiting, 3 terminated. 30 Phase 2, 11 Phase 3, 10 Phase 1, 5 Phase 4, 1 Early Phase 1.
Follow Eflornithine: new trials by email Literature Review of Eflornithine trials Research Report on Eflornithine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomas Biospecimen Collection, Eflornithine, Lumbar Puncture - Anaplastic Oligodendroglioma, Astrocytoma, IDH-Mutant, Grade 3 | Phase 1 / Phase 2 | Recruiting | Mayo Clinic | 33 | 2026-06-23 | 2026-06-24 |
| Eflornithine (DFMO) for Ewing Sarcoma and Osteosarcoma Eflornithine, Topotecan, Cyclophosphamide - Osteosarcoma, Ewing Sarcoma | Phase 2 | Recruiting | Milton S. Hershey Medical Center | 406 | 2026-06-05 | 2026-10-06 |
| Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas Eflornithine (DFMO), AMXT 1501 Dicaprate - Atypical Teratoid/Rhabdoid Tumor, Embryonal Tumor With Multilayered Rosettes | Phase 1 / Phase 2 | Recruiting | Milton S. Hershey Medical Center | 265 | 2026-05-13 | 2026-09-03 |
| Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors AMXT 1501 Dicaprate, DFMO, Fulvestrant - Melanoma (Skin Cancer), HER2-low Hormone Receptor Positive Breast Cancer | Phase 1 / Phase 2 | Recruiting | Aminex Therapeutics, Inc. | 92 | 2026-01-26 | 2026-10-22 |
| Comparison of a Face Cream Plus a Laser Procedure and Face Cream Alone in Treatment of Excessive Face Hairs in Female Eflornithine Topical, Instense pulsed light - Hirsuitism | Phase 4 | Recruiting | Khyber Teaching Hospital | 122 | 2025-07-15 | 2025-07-03 |
| DFMO Maintenance for Patients With Relapsed/Refractory Ewing Sarcoma or Osteosarcoma DFMO - Osteosarcoma Recurrent, Ewing's Tumor Recurrent | Phase 1 / Phase 2 | Recruiting | Montefiore Medical Center | 15 | 2025-04-07 | 2026-05-14 |
| Targeting ODC as an Immunotherapeutic Target in STK11 (LKB1) Pathway-Deficient NSCLC (DFMO) Pembrolizumab, Difluoromethylornithine - Non Small Cell Lung Cancer, Lung Cancer | Phase 1 / Phase 2 | Suspended | H. Lee Moffitt Cancer Center and Research Institute | 45 | 2024-08-07 | 2026-03-06 |
| Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer DFMO, testosterone cypionate, Luteinizing hormone-releasing hormone (LHRH) analogue - Prostate Cancer | Phase 2 | Recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 50 | 2023-10-04 | 2026-01-14 |
| Intratumoral Extracellular Metabolic Impact of DFMO and AMXT 1501 in Patients With Diffuse or High Grade Glioma Biospecimen Collection, Computed Tomography, Eflornithine - Diffuse Glioma, Malignant Glioma | Early Phase 1 | Recruiting | Mayo Clinic | 18 | 2023-10-01 | 2025-11-04 |
| Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma Eflornithine (Dose Level 1), Eflornithine (Dose Level 2), Eflornithine (Dose Level -1) - Glioblastoma, IDH-wildtype, Glioblastoma | Phase 1 | Recruiting | Orbus Therapeutics, Inc. | 66 | 2023-07-24 | 2025-06-25 |
| Randomized Split-Face Controlled Study to Evaluate the Effectiveness of Topical Eflornithine 9.58% + Hydroquinone 4% + Fluocinolone 0.01% as Compared to Topical Tretinoin 0.05% + Hydroquinone 4% + Fluocinolone 0.01% for the Treatment of Melasma Eflornithine 9.58% + Hydroquinone 4% + Fluocinolone 0.01% cream, Tretinoin 0.05% + hydroquinone 4% + fluocinolone 0.01% cream - Melasma, Melasma (Facial Melasma) | Phase 2 | Completed | National Skin Centre | 30 | 2023-06-06 | 2026-10-15 |
| TArgeting Type 1 Diabetes Using POLyamines (TADPOL) DFMO, Placebo - Type 1 Diabetes | Phase 2 | Active not recruiting | Emily K. Sims | 74 | 2023-03-14 | 2026-08-21 |
| DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma Difluoromethylornithine - Medulloblastoma | Phase 2 | Recruiting | Giselle Sholler | 118 | 2021-03-29 | 2026-08-12 |
| Topical Diclofenac and Topical DFMO Chemoprevention Trial in Subjects With a History of Skin Cancer Solaraze and Vaniqa - Non-melanoma Skin Cancer | Phase 2 | Completed | University of Alabama at Birmingham | 64 | 2021-01-18 | 2025-12-17 |
| Topical Eflornithine for Pseudofolliculitis Barbae: Randomized Controlled Trial Eflornithine Topical, Placebo Eflornithine Topical - Pseudofolliculitis Barbae | Phase 4 | Terminated | Walter Reed National Military Medical Center | 9 | 2020-09-27 | 2024-01-31 |
| Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma Eflornithine - Neuroblastoma | Phase 2 | Active not recruiting | Giselle Sholler | 131 | 2020-09-25 | 2026-09-03 |
| Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory Neuroblastoma Dinutuximab, Eflornithine Hydrochloride, Irinotecan Hydrochloride - High Risk Neuroblastoma, Recurrent Neuroblastoma | Phase 2 | Active not recruiting | Children's Oncology Group | 94 | 2019-07-08 | 2026-02-18 |
| Chemoprevention of Gastric Carcinogenesis Eflornithine, Eflornithine placebo - Gastric Cancer, Gastric Intestinal Metaplasia | Phase 2 | Completed | Vanderbilt-Ingram Cancer Center | 91 | 2016-09-19 | 2026-09-02 |
| Study to Evaluate Eflornithine + Lomustine vs Lomustine in Recurrent Anaplastic Astrocytoma (AA) Patients Eflornithine, Lomustine - Anaplastic Astrocytoma, Recurrent Anaplastic Astrocytoma | Phase 3 | Unknown | Orbus Therapeutics, Inc. | 343 | 2016-07-01 | 2022-01-21 |
| Neuroblastoma Maintenance Therapy Trial Difluoromethylornithine (DFMO) - Neuroblastoma | Phase 2 | Active not recruiting | Giselle Sholler | 441 | 2016-02-01 | 2026-09-03 |
Showing 20 of 50. Sign in to see all of them.
Neuroblastoma (9) · Trypanosomiasis, African (5) · Adenomatous Polyposis Coli (3) · Astrocytoma (3) · Glioma (3) · Hirsutism (3) · Precancerous Conditions (3) · Prostatic Neoplasms (3) · Carcinoma, Basal Cell (2) · Colorectal Neoplasms (2) · Diabetes Mellitus, Type 1 (2) · Glioblastoma (2) · Medulloblastoma (2) · Neuroectodermal Tumors, Primitive (2) · Osteosarcoma (2)
Giselle Sholler (8) · National Cancer Institute (NCI) (4) · Cancer Prevention Pharmaceuticals, Inc. (3) · Drugs for Neglected Diseases (3) · Epicentre (2) · Mayo Clinic (2) · Milton S. Hershey Medical Center (2) · Orbus Therapeutics, Inc. (2) · University of Alabama at Birmingham (2) · University of Arizona (2) · University of Wisconsin, Madison (2) · Allergan (1) · Aminex Therapeutics, Inc. (1) · Bispebjerg Hospital (1) · Children's Oncology Group (1)
United States (36) · Canada (8) · Republic of the Congo (3) · Australia (2) · Belgium (2) · Democratic Republic of the Congo (2) · Germany (2) · Netherlands (2) · Puerto Rico (2) · Uganda (2) · United Kingdom (2) · Central African Republic (1) · Denmark (1) · France (1) · Honduras (1)
Giselle Sholler, MD (5) · Gerardo Priotto, MD, MPH (2) · Terence C. Burns, MD, PhD (2) · Alfred M. Cohen, M.D. (1) · Alice Lee, MD (1) · Carol Burke, M.D. (1) · Craug Elmets, MD (1) · David S. Alberts, MD (1) · Dean E. Brenner, MD (1) · Deyaa Adib, MD (1) · Donald A. Urban, MD (1) · Doug Morgan, MD (1) · Elisabeth H Taudorf, MD (1) · Els Torreele, PhD (1) · Emily K Sims, MD,MS (1)
PMID 32391579, PMID 38917371, PMID 10024506, PMID 10433086, PMID 10605821, PMID 10852253, PMID 11208527, PMID 11564949, PMID 11815483, PMID 12972423, PMID 15972654, PMID 16011702, PMID 16714282, PMID 17214730, PMID 1730582, PMID 17524725, PMID 18176934, PMID 18268112, PMID 18360702, PMID 19188144, PMID 19559476, PMID 19763038, PMID 19968980, PMID 19997760, PMID 20127992, PMID 20405312, PMID 20501948, PMID 20538001, PMID 20956533, PMID 21147316, PMID 21389784, PMID 22442300, PMID 23209861, PMID 23250488, PMID 25792707, PMID 26018967, PMID 26397425, PMID 26712942, PMID 2891995, PMID 29113731, PMID 3093066, PMID 3105526, PMID 3128541, PMID 31986140, PMID 32506485, PMID 32715853, PMID 32905675, PMID 34214479, PMID 34261858, PMID 34522028
P01CA027502 (2), P30CA016672 (2), 2004 (1), P01CA081403 (1), P30CA015083 (1), P30CA023074 (1), P30CA046592 (1), R01CA088078 (1), R01CA113681 (1), R01CA190612 (1), R01CA193885 (1), R37CA276851 (1), U01CA077158 (1), U10CA037429 (1), U10CA180886 (1)